Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized-withdrawal study of TD-9855 for symptomatic neurogenic orthostatic hypotension in primary autonomic failure
MOH_2019-10-28_007254Phase 3Recruiting
- Sponsor
- Theravance Biopharma, Inc.
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Neurogenic Orthostatic Hypotension (nOH) comparing Open-label TD-9855 followed by randomized TD-9855 with Open-label TD-9855 followed by randomized placebo (2 arms). Started Jul 2019; status: recruiting.
02
Drugs
ampreloxetine
03
Conditions
Neurogenic Orthostatic Hypotension (nOH)
Beyond the preview
Go deeper on MOH_2019-10-28_007254.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-10-28_007254.